PNC-27
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Chimeric anticancer peptide containing p53 residues 12-26 fused to a penetratin leader sequence; selectively kills cancer cells by targeting membrane-associated HDM-2.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | p53-penetratin chimeric peptide 27 |
| Category | Anticancer Peptide (Cancer Therapeutic) |
| Sequence | Penetratin leader + p53 residues 12-26 (PPLSQETFSDLWKLL); 32 amino acids total |
| Molecular Weight | ~3800 Da (estimated) |
| Molecular Formula | Not publicly disclosed |
| PubChem CID | N/A (research compound) |
| Administration | Intratumoral (research); systemic delivery under development |
| Typical Dose Range | Micromolar concentrations (in vitro); no clinical dosing established |
| Half-Life | Not characterized in humans |
| Storage | Lyophilized at -20C; reconstituted at 2-8C |
| FDA Status | Research-only — preclinical stage; no clinical trials registered |
| WADA Status | Not listed |
Mechanism of Action
PNC-27 is a rationally designed 32-residue chimeric peptide that exploits a fundamental difference between cancer and normal cells: the expression of HDM-2 (human double minute 2, also called MDM2) on the plasma membrane.
Structural Design: PNC-27 consists of two functional domains:
- p53 HDM-2-binding domain (residues 12-26 of p53) — This alpha-helical segment mimics the natural p53-MDM2 interaction interface, binding to HDM-2 with high affinity
- Penetratin leader sequence — A cell-penetrating peptide (CPP) derived from the Antennapedia homeodomain that enables membrane interaction and pore formation
Cancer Cell Selectivity: The key insight underlying PNC-27 is that cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells sequester HDM-2 in the nucleus where it functions as a p53 negative regulator (PMID: 20080680). This membrane-associated HDM-2 provides a cancer-specific surface target.
Mechanism of Killing ("Poptosis"):
- PNC-27 adopts an alpha-helical conformation and binds to membrane-associated HDM-2 on cancer cell surfaces
- The penetratin domain inserts into the lipid bilayer
- Multiple PNC-27 molecules oligomerize at the membrane, forming transmembrane pores
- Rapid membrane disruption occurs, leading to cell lysis and necrotic death
- LDH release confirms necrotic (not apoptotic) cell death
This mechanism has been termed "poptosis" (peptide-induced transmembrane pore formation) and is fundamentally distinct from apoptosis-based cancer therapies (PMID: 35625682). Because many advanced cancers develop apoptosis resistance, a necrotic killing mechanism may bypass this resistance.
Key Research Areas
- Selective Cancer Cell Killing — Demonstrated cytotoxicity against breast (MDA-MB-468), pancreatic (PANC-1), melanoma (A375), leukemia (K562, HL60), ovarian, and cervical cancer lines while sparing normal cells (PMID: 20080680, 32878773, 40750238)
- Membrane HDM-2 Biology — Characterizing why cancer cells express HDM-2 on their membranes and how this relates to oncogenesis
- Hematologic Malignancies — PNC-27 kills leukemia cells (K562, HL60) but not normal hematopoietic cells (PMID: 32878773)
- Drug Delivery Enhancement — PNC-27 used as a targeting ligand for doxorubicin-loaded liposomes (Doxil), improving antitumor efficacy (PMID: 28565974)
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 0 | No clinical trials |
| Human observational | 0 | — |
| Animal in vivo | 0 | In vivo data via PNC-28 (related peptide) |
| In vitro | 3 | Multiple cancer cell lines tested |
| Systematic reviews | 0 | — |
Clinical Applications
- Cancer Adjunct Therapy — Preclinical anticancer agent targeting membrane HDM-2
Protocols Using This Peptide
- No established clinical protocols. Research use only.
Ageless Peps Products
- No Ageless Peps product currently available for PNC-27.
Dosing Reference
Research Dosing Ranges (from literature)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| In vitro | 50-200 uM | Single exposure | 24-72 hours | PMID 20080680 |
Cycling
No cycling protocols established — preclinical stage only.
Contraindications & Safety
- Contraindications: Not established (preclinical compound)
- Common side effects: Not characterized in humans
- Drug interactions: Unknown; theoretical synergy with conventional chemotherapy
- Pregnancy/nursing: Not studied; contraindicated as research chemical
- Special populations: Not studied
Synergistic Combinations
- PNC-28 — Related peptide with overlapping but distinct HDM-2 binding profile; potential for complementary targeting
- Conventional chemotherapy — PNC-27-conjugated liposomal doxorubicin showed enhanced efficacy (PMID: 28565974)
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 20080680 | PNC-27 Kills Cancer Cells via Membrane HDM-2 Binding (PNAS) | 2010 | In vitro |
| 35625682 | Chimeric p53-Penetratin Peptide: Membrane-Pore Formation | 2022 | In vitro / Review |
| 32878773 | PNC-27 Induces Necrosis in Leukemia but Not Normal Cells | 2020 | In vitro |
References
- PMID 20080680 — Foundational PNAS paper: HDM-2 membrane binding and cancer cell selectivity
- PMID 35625682 — Structural characterization and poptosis mechanism (Biomedicines 2022)
- PMID 32878773 — Leukemia cell killing with normal hematopoietic cell sparing
- PMID 28565974 — PNC-27 as targeting ligand for Doxil (liposomal doxorubicin)
- PMID 20182728 — PNC-27 induces tumor cell lysis as intact peptide
- PMID 40750238 — PNC-27 kills cervical cancer cells but not normal cells (2025)
Related
Research Purposes Only. PNC-27 is a preclinical research compound. It has not been tested in humans and is not approved for any clinical use. All data is derived from in vitro cell culture studies.
#peptide #cancer-therapeutic #not-sold